BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses
- New goal represents one-quarter increase from prior estimate
- BioNTech shares gain as company reports first annual profit
This article is for subscribers only.
BioNTech SE and Pfizer Inc. raised this year’s production target for their Covid-19 vaccine to as many as 2.5 billion doses, with the German biotech company’s chief predicting a version of the shot that can be stored in refrigerators will be ready within months.
The new target represents an increase of about one quarter from the company’s earlier estimate.